$GLUE News

Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?

Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study

Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk - Slideshow

HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript

Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

Monte Rosa Reports Data From GFORCE-1, Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NEK7/NLRP3 Pathway

GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?

HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone

Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer